Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
NCT ID: NCT01990300
Last Updated: 2023-09-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3281 participants
OBSERVATIONAL
2011-11-28
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"
NCT02003014
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
NCT00286494
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
NCT00655863
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
NCT02989649
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be patients with type 2 diabetes mellitus. The planned sample size is 3000.
The usual adult dosage is 1 tablet (containing alogliptin/pioglitazone at either 25 mg/15 mg or 25 mg/30 mg) taken orally once daily before or after breakfast.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alogliptin/Pioglitazone combination tablets
Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
Alogliptin/Pioglitazone
Alogliptin/Pioglitazone combination tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alogliptin/Pioglitazone
Alogliptin/Pioglitazone combination tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1. Patients with current cardiac failure or a past history of cardiac failure
2. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus
3. Patients with serious hepatic dysfunction
4. Patients with serious renal dysfunction
5. Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury
6. Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
7. Pregnant or possibly pregnant women
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Someplace, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JapicCTI-132302
Identifier Type: REGISTRY
Identifier Source: secondary_id
136-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.